title: The benefits and risks of using a levonorgestrel-releasing intrauterine system for contraception.
abstract: The contraceptive profile of the levonorgestrel-releasing intrauterine system (LNG-IUS; Mirena®) is well established, with efficacy similar to that achieved with sterilization and rapid return to fertility after discontinuation of use. The LNG-IUS is typically associated with transient menstrual disturbance during the first few months of use, but this usually settles with continued use, with a concomitant decrease in menstrual blood loss. Overall, the safety profile of the LNG-IUS has been well established across a wide population of women, and the available data do not suggest that the LNG-IUS adversely affects bone health or increase the risk of adverse cardiovascular events or breast and uterine cancers. This article reviews the literature to provide updated information on the risks and benefits associated with the LNG-IUS, particularly focusing on its use in contraception.
authors: New Croft Centre, NE1 6ND Newcastle upon Tyne, UK. diana.mansour@newcastle-pct.nhs.uk
authors: Diana
authors: D
authors: Mansour
mesh_terms: D003271:Contraceptive Agents, Female / Q000008:administration & dosage* / Q000009:adverse effects; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D007436:Intrauterine Devices, Medicated / Q000009:adverse effects* / Q000191:economics; D016912:Levonorgestrel / Q000008:administration & dosage* / Q000009:adverse effects; D018570:Risk Assessment
chemical_list: D003271:Contraceptive Agents, Female; D016912:Levonorgestrel